What FDA GLP-1 Compounding Changes Mean for 503A Pharmacies

GLP-1 medications have created one of the most important shifts in the compounding pharmacy market in years. Demand for medications such as semaglutide and tirzepatide pushed many pharmacies, prescribers, telehealth groups, and patients into fast-moving workflows that were not always built for long-term operational control.

Now, FDA activity around GLP-1 compounding is forcing many pharmacy owners to ask a practical question: Is our pharmacy’s intake and documentation process strong enough for the level of attention this category is receiving?

This article explains what 503A pharmacy owners should know, why workflow control matters, and how a prescriber portal can help compounding pharmacies manage orders more efficiently.

What changed with GLP-1 compounding?

FDA has clarified policies for compounders as national GLP-1 supply has stabilized. FDA also announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, stating that it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances.

Pharmacy owners should read the FDA updates directly:

• FDA: Clarifies policies for compounders as national GLP-1 supply begins to stabilize
• FDA: Proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
• FDA: Human Drug Compounding Laws

These updates do not mean every compounding pharmacy has the same obligations in every situation. However, they do show that GLP-1 compounding is under close review and that pharmacies should pay careful attention to federal requirements, state board requirements, documentation, and patient-specific prescription workflows.

503A vs. 503B: why the distinction matters

One reason GLP-1 compounding can be confusing is that 503A pharmacies and 503B outsourcing facilities operate under different federal sections of the Federal Food, Drug, and Cosmetic Act.

503A pharmacies

A 503A compounding pharmacy is typically a state-licensed pharmacy that compounds medications based on patient-specific prescriptions. In practical terms, this means the pharmacy’s workflow should be built around individual patients, prescribers, prescriptions, documentation, and pharmacist review.

503B outsourcing facilities

A 503B outsourcing facility is a different type of entity that may compound sterile drugs under a separate federal framework. FDA’s proposed action related to semaglutide, tirzepatide, and liraglutide specifically addresses the 503B Bulks List.

For 503A pharmacies, the broader message is still relevant: GLP-1 compounding is being watched closely, and pharmacies need clean workflows that support patient-specific ordering, documentation, and communication.

Why manual GLP-1 intake workflows are harder to defend

Many compounding pharmacies still receive prescriptions through a mix of fax, phone calls, email, PDF forms, website forms, handwritten notes, and direct prescriber conversations. That can work at low volume, but it becomes difficult as prescription volume increases.

Manual intake creates several common problems:

• Missing information: Patient, prescriber, medication, dose, quantity, allergies, or shipping information may be incomplete.
• Slow clarification: Pharmacy staff may need multiple calls or messages to clarify one order.
• Limited visibility: Prescribers and clinic staff may not know whether an order was received, in progress, ready, or shipped.
• Scattered records: Documentation may live across fax inboxes, emails, call notes, pharmacy software, and spreadsheets.
• Harder audits: It may be more difficult to reconstruct who submitted an order, what was requested, when it was reviewed, and how questions were resolved.

These issues are not limited to GLP-1s. They apply to many areas of compounding, including hormone therapy, dermatology, pain management, veterinary compounds, thyroid, oral health, and fully custom compounds.

Why pharmacy-controlled workflows matter

A pharmacy-controlled workflow gives the pharmacy more structure over how compound orders are submitted and managed. Instead of relying only on faxes and phone calls, the pharmacy can guide prescribers through a defined ordering process.

For pharmacy owners, this matters because the pharmacy is still responsible for reviewing prescriptions, validating required information, following applicable laws and rules, and maintaining appropriate records. A better workflow does not replace pharmacist judgment, but it can help the team collect information more consistently.

How a prescriber portal helps 503A compounding pharmacies

A prescriber portal gives doctors, clinic staff, and pharmacy teams a shared digital workflow for compound order intake. Instead of sending every order through a fax machine or an email inbox, the prescriber can submit orders through a structured portal that is designed around the pharmacy’s compound catalog and ordering rules.

1. Cleaner prescriber intake

A portal can help collect the core information needed to start the pharmacy review process, including prescriber, patient, medication, strength, dosage form, SIG, quantity, refills, notes, and attachments.

2. Faster reorders

Many compound prescriptions are reordered. A portal can allow prescribers or authorized clinic users to reorder commonly used compounds more efficiently, reducing repetitive phone calls and manual data entry.

3. Better communication

Secure messaging between the pharmacy and prescriber can help clarify questions without relying only on phone tag, faxes, or unsecured email.

4. Order status visibility

Prescribers often want to know whether an order was received, is being processed, is ready, or has shipped. A portal can give clinics better visibility while reducing routine status calls to the pharmacy.

5. More organized documentation

A portal can help centralize order details, messages, attachments, timestamps, and order activity. This can support a more organized internal workflow for the pharmacy team.

What 503A pharmacies should review now

Pharmacy owners should review their GLP-1 workflows as part of a broader compounding operations review. The goal is not only to respond to one medication category, but to improve how the pharmacy manages compound orders overall.

1. Review current GLP-1 policies. Confirm how your pharmacy evaluates GLP-1 prescriptions, shortage status, patient-specific requirements, and applicable federal and state rules.
2. Review prescriber intake forms. Look for missing fields, unclear instructions, outdated forms, and inconsistent submission channels.
3. Review documentation practices. Confirm where prescription details, communications, clarifications, and attachments are stored.
4. Review staff workload. Identify how much time your team spends on calls, faxes, order clarification, refill requests, and status updates.
5. Review prescriber experience. Ask whether your current process makes it easy for providers to submit orders correctly the first time.
6. Review technology gaps. Determine whether your pharmacy needs a more modern prescriber ordering workflow.

Why this is bigger than GLP-1s

GLP-1 compounding may be the current high-interest topic, but the operational lesson is much broader. Compounding pharmacies need workflows that can scale across categories, prescribers, locations, and patient needs.

A pharmacy that modernizes its ordering process can be better positioned to support multiple compounding categories, including:

• Dermatology compounds
• Men’s hormone replacement therapy
• Women’s hormone replacement therapy
• Veterinary compounds
• Ocular health compounds
• Pain management compounds
• Thyroid compounds
• Oral health compounds
• Custom compounds

The same workflow problems that affect GLP-1 orders can affect every compound category: incomplete intake, slow clarification, disconnected communication, and limited prescriber visibility.

How PharmacyLive supports compounding pharmacies

PharmacyLive helps compounding pharmacies offer a modern prescriber ordering experience. The platform is designed to help prescribers submit compound orders, communicate with the pharmacy, track order progress, reorder more efficiently, and work within a pharmacy-controlled workflow.

PharmacyLive is especially useful for pharmacies that want to reduce reliance on manual faxes, improve prescriber experience, and create a more organized intake process for custom compounds.

PharmacyLive can support pharmacies using PioneerRx and other pharmacy systems, or operate as a standalone ordering platform depending on the pharmacy’s workflow needs.

Final thoughts

FDA activity around GLP-1 compounding is a reminder that compounding pharmacies need strong workflows, clear documentation, and a better way to manage prescriber ordering. For 503A pharmacies, the opportunity is to move beyond scattered faxes and manual intake toward a more organized, pharmacy-controlled process.

PharmacyLive helps compounding pharmacies modernize that process with a prescriber portal built around compound ordering, pharmacy communication, and order visibility.

For product updates, pharmacy workflow ideas, and compounding pharmacy technology insights, follow PharmacyLive on LinkedIn: https://www.linkedin.com/company/pharmacylive/

Sources

• FDA: Clarifies policies for compounders as national GLP-1 supply begins to stabilize
• FDA: Proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
• FDA: Human Drug Compounding Laws
• FDA: Human Drug Compounding

Disclaimer: This article is provided for general educational purposes only and does not constitute legal, regulatory, clinical, billing, or compliance advice. Compounding pharmacies should consult qualified legal, regulatory, and clinical advisors regarding their specific operations and obligations.